Titre : | Missed Opportunities for Hepatitis C Testing in Opioid Treatment Programs. (2013) |
Auteurs : | FRIMPONG (Jemima-A) : USA. Department of Health Policy and Management. Mailman School of Public Health. Columbia University. New York. NY. |
Type de document : | Article |
Dans : | American journal of public health (vol. 103, n° 6, 2013) |
Pagination : | 1028-1030 |
Langues: | Anglais |
Mots-clés : | Hépatite virale C ; Evaluation ; Qualité ; Dépistage ; Thérapeutique ; Programme ; Virose ; Infection |
Résumé : | [BDSP. Notice produite par INIST-CNRS FoR0xFCo. Diffusion soumise à autorisation]. HCV has surpassed HIV as a cause of death in the United States and is particularly prevalent among injection drug users. I examined the availability of on-site HCV testing in a nationally representative sample of opioid treatment programs. Nearly 68% of these programs had the staff required for HCV testing, but only 34% offered on-site testing. Availability of on-site testing increased only slightly with the proportion of injection drug users among clients. The limited HCV testing services in opioid treatment programs is a key challenge to reducing HCV in the US population. |